A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT05344469
- Locations
- 🇩🇪
Novartis Investigative Site, Wolfratshausen, Germany
Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 277
- Registration Number
- NCT05344482
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
- Conditions
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 175
- Registration Number
- NCT05335876
- Locations
- 🇺🇸
Child Hosp Of The Kings Daughters, Norfolk, Virginia, United States
🇻🇳Novartis Investigative Site, Hanoi, Vietnam
A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT05334472
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT05330286
- Locations
- 🇬🇧
Novartis Investigative Site, Mere Way, Nottingham, United Kingdom
A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT05329623
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT05330273
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT05328752
- Locations
- 🇺🇸
Jacksonville Ctr for Clin Rea Main Centre, Jacksonville, Florida, United States
🇳🇱Novartis Investigative Site, Groningen, Netherlands
🇺🇸Nature Coast Clinical Research LLC, Inverness, Florida, United States
Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17743
- Registration Number
- NCT05320159
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05304949
- Locations
- 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of